We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety and Effects of Ramipril Combined With Candesartan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00356395
Recruitment Status : Completed
First Posted : July 26, 2006
Last Update Posted : July 26, 2006
Information provided by:
Gachon University Gil Medical Center

Brief Summary:
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: ramipril, candesartan Phase 4

Detailed Description:
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients
Study Start Date : August 2003
Estimated Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. comparison of endothelium-dependent dilation among the 3 treatment schemes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with mild to moderate hypertension

Exclusion Criteria:

  • We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356395

Sponsors and Collaborators
Gachon University Gil Medical Center
Principal Investigator: Kwang K Koh, MD Cardiology, Gil Heart Center, Gachon Medical School

ClinicalTrials.gov Identifier: NCT00356395     History of Changes
Other Study ID Numbers: 2003-008
First Posted: July 26, 2006    Key Record Dates
Last Update Posted: July 26, 2006
Last Verified: March 2006

Keywords provided by Gachon University Gil Medical Center:
endothelial function, insulin resistance, adipocytokines

Additional relevant MeSH terms:
Candesartan cilexetil
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors